This reduction in OATP1B1 and OATP1B3 levels impairs sorafenib sensitivity in HCC cells, thereby contributing to sorafenib resistance at high NIFK-AS1 levels [143]. This evidence concerns the gene NIFK and hepatocellular carcinoma.